Physician

Tejas Suresh, M.D.

According to 2025 Medicare claims, Tejas Suresh, M.D. (NPI: 1679836365) practices hematology/oncology in the Arlington-Alexandria-Reston, VA-WV market, with the plurality of this provider's patient population coming from Fauquier, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER SPECIALISTS, P.C. (NPI: 1346294519; TIN: 541795091) and primary practice location at 20186-3009.

Suresh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 672 traditional Medicare patients, billed 162,126 HCPCS/CPT codes, and received $2,979,456 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,119 prescription claims across 183 beneficiaries totaling $2,122,846 in drug costs, led by Lenalidomide (Lenalidomide). 2023 DME data shows 15 claims. Open Payments data shows 74 records totaling $2,438. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $28,221 to $2,979,456. Similarly, Part D prescription costs have moved sharply higher in recent years, from $3,068 to $2,122,846. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	112	353	$28,221
2016	149	544	$44,198
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	179	2,115	$58,779
2020	455	3,656	$275,398
2021	742	66,670	$1,224,373
2022	667	237,031	$3,002,444
2023	672	136,633	$2,629,614
2024	672	162,126	$2,979,456

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	29	90	$3,068
2016	39	110	$3,366
2017	39	112	$10,051
2018	30	58	$14,493
2019	23	73	$96,527
2020	79	501	$541,984
2021	117	554	$930,111
2022	118	642	$616,162
2023	145	905	$1,643,755
2024	183	1,119	$2,122,846

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	72	$41,161
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	49	$4,862
2021	N/R	28	$2,183
2022	N/R	41	$1,332
2023	N/R	15	$2,449
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	126	331	$98
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	200	473	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	194	242	$63
36415	Insertion of needle into vein for collection of blood sample	297	1,086	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	287	1,158	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	58	1,533	$687,404
Lenvima	Lenvatinib Mesylate	11	330	$247,161
Lumakras	Sotorasib	13	390	$159,393
Brukinsa	Zanubrutinib	12	360	$113,411
Eliquis	Apixaban	73	3,510	$66,131

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	74	$2,438	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Tejas Suresh, M.D.?

Tedicare shows public-source Medicare data for Tejas Suresh, M.D. (NPI 1679836365), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Tejas Suresh, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Tejas Suresh, M.D.?

Tejas Suresh, M.D. is linked to VIRGINIA CANCER SPECIALISTS, P.C. (billing NPI 1346294519) in the available physician profile data.

Does Tejas Suresh, M.D. have Open Payments data?

Tejas Suresh, M.D. has 74 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.